A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
Cardiovascular and renal complications remain leading causes of morbidity and mortality among individuals with type 2 diabetes mellitus (T2DM). Since 2015, large-scale cardiovascular outcome trials (CVOTs) have demonstrated that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like pe...
- Autores:
-
Aristizábal-Colorado, David
Corredor-Rengifo, David
Sierra Castillo, Santiago
López-Corredor, carolina
Vernaza Trujillo, David Alexander
Weir-Restrepo, Danilo
Izquierdo-Condoy, Juan S.
Ortiz-Prado, Esteban
Rico-Fontalvo, Jorge
Gómez-Mesa, Juan Esteban
Abreu Lomba, Alin
Rivera Martínez, Wilfredo Antonio
- Tipo de recurso:
- Fecha de publicación:
- 2025
- Institución:
- Universidad Simón Bolívar
- Repositorio:
- Repositorio Digital USB
- Idioma:
- eng
- OAI Identifier:
- oai:bonga.unisimon.edu.co:20.500.12442/16821
- Acceso en línea:
- https://hdl.handle.net/20.500.12442/16821
https://doi.org/10.3389/fendo.2025.1605746
https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1605746/full
- Palabra clave:
- Cardiovascular outcomes
SGLT2 inhibitors
GLP-1 agonists
Combination therapy
Heart failure
Renal outcomes
- Rights
- openAccess
- License
- Attribution-NonCommercial-NoDerivatives 4.0 International